Following the Engage trial - the largest double-blind fertility agent trial performed to date - Merck & Co. Inc. announced European Commission approval for ELONVA, indicated for controlled ovarian stimulation in combination with a GnRH antagonist, in assisted reproductive technology (ART) programmes.
Full article